IRVINE, Calif., July 18, 2007 (PRIME NEWSWIRE) -- A comprehensive report focusing on TapImmune (OTCBB:TPIM) and developments in immunology and immunotherapy has been published by financial courier StockUpTicks.com and is available free of charge to the investing public.
The report will feature detailed information regarding TPIM and address related information and companies Dendreon Corp. (Nasdaq:DNDN), Biovail Corp. (NYSE:BVF), and Genentech (NYSE:DNA).
"TapImmune's recent relaunch was met with a meteoric rise in stock price," stated SmallCap Sentinel analyst D.R. Clark. "We'll be following the TapImmune story closely."
To view the report in its entirety, please visit:
http://stockupticks.com/profiles/7-17-07.html
TapImmune Inc. ("TapImmune" "TPIM") is a biotechnology company specializing in the development of innovative therapeutics and vaccines in the areas of oncology and infectious disease. TPIM technologies are based on an understanding of the function of a protein "pump" within cells that is essential in the processing of tumor antigens, known as TAP. Transporters Associated with Antigen Processing (TAP) are transporters responsible for supplying tumor-associated antigens and viral antigens used in the assembly of MHC class I surface molecules. MHC class I molecules are required for the recognition and destruction of tumor cells and virus infected cells by the cellular arm of the immune system. A wide variety of metastatic cancers evade destruction by the immune system due to absent or insufficient amounts of TAP, making the tumors unrecognizable by the immune system.
TPIM's lead product, the TAP vaccine performs a key step in moving characteristic markers called antigens to the surfaces of cells allowing the subsequent recognition and killing of cancer cells by the immune system. Without TAP, there are no cancer markers, so the immune system fails to spot the rogue cells and the cancerous cells can grow undetected.
TapImmune's corporate website has recently been updated and includes access to major media coverage of TapImmune and its science:
Statements herein contain forward-looking statements and are subject to significant risks and uncertainties affecting results. SmallCap Sentinel/StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect proposed actions and cannot project capabilities, intent, resources, or experience.
The SmallCap Sentinel logo is available at http://www.primenewswire.com/newsroom/prs/?pkgid=3664
All information contained herein is based upon sources believed to be reliable but no representation is made as to accuracy or completeness. This report is neither a solicitation to buy nor an offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid 100,000 restricted common shares of TPIM and $10,000 U.S. for preparation and distribution of this report and other advertising services over a ninety day period. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject company.